MeiraGTx Secures $400 Million Funding Boost from Oberland Capital

The deal delivers $375 million in non-dilutive capital structured around capped royalty payments, alongside a $25 million equity investment. Oberland Capital will provide an initial $135 million immediately, with subsequent funding tranches contingent upon positive clinical data readouts and the successful progression of regulatory approvals for MeiraGTx’s in-development portfolio.

Michael Bloom, a partner at Oberland Capital, pointed to the company’s near-term pipeline—specifically three therapies expected to reach approval within two years—as the primary driver for the investment. Following the announcement, MeiraGTx shares rose 4.4% to $14.50 in premarket trading. CEO Alexandria Forbes noted that the multi-product structure allows the firm to secure substantial liquidity without sacrificing long-term business development flexibility.